If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market,
Chemistree Technology’s (CHM.C) investee life-science company involved in pharma-grade natural health products, ImmunoFlex, received the Health Canada nod earlier this week for their FLEX 10
Pure Extracts Technologies (PULL.C) set their milestone timetable for their study on both the formulation and manufacturing of psilocybin-based treatments today, according to a press
Mind Medicine (MMED.E) announced earlier this week their intention to conduct a randomized placebo-controlled study using LSD to evaluate certain health and cognitive effects according
Field Trip Health (FTRP.C) closed a bought deal short form prospectus offering, pulling in $20,016,900 today, according to a press release. The company issued 4,448,200
Mydecine Innovations Group (MYCO.C) announced that they were sponsoring a study called “The neurocognitive effects of low dose psychoactive substances,” at Macquary University in Australia
Pure Extracts Technologies (PULL.C) commenced a study on the formulation and manufacturing of psilocybin-based treatments today, according to a press release. The products will come
Mind Cure Health (MCUR.C) released its latest formulation, an all-natural supplement called Mind Cure Teen today, according to a press release. Mind Cure Teen is
Before we start, let’s give a big round of applause to Immunoprecise Antibodies Ltd and all its staff and its management. They are headed to
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
In my experience with the North American public markets, few companies and executive teams got more lucky with their shareholder base than Lifestyle Delivery Systems.
Jody Vance once again dives deeper into some of small caps most interesting stories. In this episode, Jody speaks with Valeo Pharma (VPH.C) president and
If this was a 1990’s news website we’d be putting all sorts of animated siren gifs all over the top of this piece because, I
Empower Clinics’ (CBDT.C) Kai Laboratory will launch their FDA approved, at-home or work saliva COVID-19 RT-PCR test on December 15, according to a press release.
PILL is developing solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in multiple doses and timed-release combinations
New Wave Holdings (SPOR.C) entered a joint venture with the University of West Indies for drug discovery and improve knowledge of medicinal plants in Jamaica,
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see
Before the Orphan Drug Act was introduced in 1983, Big Pharma ignored rare diseases, leaving people suffering from chronic conditions such as cancer, hemophilia and
A few states in our neighbour to the south decided to offer psilocybin based therapies during the most recent spate of elections, prompting more potential
Sick democracy – sick people – big profits. That was a cogitative jump that most investors seemed to make.
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release.
Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescription and over-the-counter products.
Better Plant Sciences (PLNT.C) received a natural health product (NHP) number from Health Canada for their anti-microbial skin ointment product today, according to a press
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks
It would seem the race to find a suitable treatment for COVID-19 is over, as Gilead Sciences (GILD.Q) announced today that their antiviral drug Veklury
Revive Therapeutics (RVV.C) recent supply agreement with HAVN Life Sciences (HAVN.C) will give them a steady supply of naturally derived psychedelic compounds, like psilocybin, to
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a
Xphyto Therapeutics’ (XPHY.C) subsidiary Vektor Pharma TF GmbH has finished work on their oral disintegrating film (ODF), a dosage formulation for a major European pharma-company
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ NEW YORK, Oct.
Mind Medicine (MMED.E) is raising money to found and launch a clinical training program focused on developing psychedelic-assisted therapies and medicines at New York University’s
Deep down the insomnia rabbit hole you can hear of some fairly strange recipes for relief. You’ve got your usuals—melatonin pills, valerian root, chamomile tea,
Red Light Holland (TRIP.C) announced that their iMicrodose Packs are anticipated to be available as early as October 2020 in stores courtesy of PharmaDrug’s (BUZZ.C)
Numinus Wellness (NUMI.V) started cultivating psilocybe mushrooms for production at their 7,000 square foot Health Canada approved facility today, according to a press release. At
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with
As a student of economics, I believe the stock market at times acts like an old-style ‘beauty contest’. This theory is not new but has
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
Immunoprecise Antibodies (IPA.V) subsidiary, IPA Europe, invested in its B-Cell Select platform at its research division in Oss, the Netherlands, enabled by prior investments in
Normally when we we write about Revive Therapeutics (RVV.C), it’s generally to provide an update on their progress regarding their experimental COVID-19 palliative, Bucillamine. This
Doing what we do at Equity Guru, every day, we receive emails and dms from shareholders of different companies – all expressing their grievances. Disgruntled
Over twenty million people worldwide have contracted COVID-19. Of those 12.4 million have recovered and approximately 738,000 have died at the time of writing, according
Red Light Holland (TRIP.C) has fast-tracked its 3,000 square-foot custom-built indoor production and distribution facility in Horst, the Netherlands, and is now growing its first
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that
An independent study has determined that Ovation Science’s (OVAT.C) Dermsafe hand sanitizer lotion is effective against one of the various human coronaviruses, the beta coronavirus
Cancer focused biopharmaceutical company, Unum Therapeutics (UMRX.Q) completed their acquisition of biotech company Kiq LLC today. Kiq works on the discovery and development of kinase
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against
The ongoing COVID-19 drama that’s dragged markets to its knees may almost be over, as finally companies have made some headway and there’s a drug
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them
Puration (PURA.OTC) will acquire a CBD sexual wellness product line, the company announced today in a press release. Pura’s revenue comes mostly through the sales
Liberty Leaf Holdings (LIB.C) made a right-turn into psychedelics with their latest acquisition of Nova Mentis Biotech today. Now that mushrooms have started gathering serious
Mydecine Innovations Group (MYCO.C) signed a non-binding letter of intent to acquire NeuroPharm, a Canadian-based healthcare company involved in the nascent shroom-space earlier this week.
Numinus Wellness (NUMI.V) is the first company to receive the Health Canada nod to standardize the extraction of psilocybin from mushrooms. The Health Canada nod
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three reasons you think it’s great, and one thing you’ll openly admit they need to do better.” I got 35. Gulp.
Scientists don’t have all the answers—if they did they would be out of a job—and sometimes that answer isn’t good enough. Especially for people who
Nutritional High International (EAT.C) signed an LOI to acquire Kruzo LLC, a company involved in development and research of products surrounding the psychoactive cacti peyote,
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from
Inovio Pharmaceuticals (INO.Q) announced the publication of the preclinical study data for its COVID-19 DNA vaccine, IN0-4800, demonstrating neutralizing antibody and T-cell immune responses against
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Naturally Splendid (NSP.T) signed an LOI with Vancouver-based Biological Pharmamedical Research to form a joint venture to continue developing and pursuing phase two clinical studies,
Here’s a simple and effective investment strategy: invest in companies that sell
products with growing inelastic demand.
Champignon Brands (SHRM.C) recent term sheet with California-based Wellness Clinic of Orange County not only furthers the company’s North American clinical expansion, but gives them
We’re two months in on this pandemic and governments are thinking about reopening the economy for the summer when the traditional flu season winds down.
We’ve all seen it: the media craze about gluten and how it’s terrible for us. Except it generally lacks solid scientific consensus, and like most
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he
Neptune Wellness Solutions (NEPT.T) reported today that their phase II expansion at their Sherbrooke, Quebec, facility is online and has received approvals to run product
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.
Mind Medicine (MMED.E) started enrolling candidates for further human safety trial studies of 18-MC, the company’s orally taken ibogaine derivative for the treatment of opioid
Being working class in the United States in the time of Donald Trump is a curious endeavour. The stories coming from some of my friends
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
Roadman Investments’ (LITT.V) recent acquisition target CLOV Biopharma (CBP) is continuing its research into the potential commercial uses of cedar leaf oil vapour (CLOV), specifically
Soligenix (SNGX.Q), a biopharma company that develops and commercializes products for rare diseases, announced that its RiVax, which is a heat stable ricin toxin vaccine,
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the
Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from
The first time we dealt with a coronavirus I was a lonely college student in Oshawa, Ontario and folks around me thought briefly that the
Eli Lilly and company (LLY.NYSE) and robotic cloud-computing provider, Strateos, unveiled the Lilly Life Sciences Studio lab, a new robotic laboratory in San Diego, Calfornia,
Amgen (AMGN.Q) signed a lease with BioMed Realty for a new 240,000 square foot Leadership in Energy and Environmental Design (LEED) candidate facility in the
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth
When markets closed Friday November 15, Karuna Therapeutics (KRTX.Q) was just another pharma-stock trading in the mid-teens trying to make drugs for patients with Alzheimer’s
Johnson & Johnson (JNJ.NYSE) issued a recall for a single lot of its Baby Powder in response to a FDA test that uncovered the presence
My best friend growing up married a woman with severe rhinosinusitis and nasal polyps. That sounds about as serious as a case of the common
Cannabis has been good to us here at equity.guru. There are 1,283 pages of cannabis-related content on our site and it’s still growing. That said,
Last minute attendees can register for Cambridge House’s Extraordinary Future event here and use promocode: FUTURE30 for 30% off. The Extraordinary Future Conference – running
“Cannabis is dead; long live cannabis.” Mushrooms, mark my words.. –Ancient potstocks proverb Seriously though, folks, the cannabis sector is in trouble. Take a look
China has a bug up its ass about U.S. and Canada’s new permissive cannabis laws. Is anyone surprised? Apparently, our new easygoing attitude towards cannabis
An Oklahoma district court judge has ordered Johnson & Johnson (JNJ.NYSE) to pay $572 million for its part in the state’s opioid epidemic. Cleveland County
We all know someone who’s been touched by cancer. It’s been called the worst scourge of civilized mankind. It sweeps through a family, disrupting our
GW Pharmaceuticals (GWPH.Q) has received a recommendation from the European Medicines Agency (EMA) for the authorization of the company’s Epidyolex cannabis oral solution for use
Someone in the world develops dementia every three seconds. Alzheimer’s disease and other dementia-related disorders affect 50M people around the world and that number is
According to the World Health Organization, around 50 million people suffer from dementia worldwide and nearly 10 million new cases are diagnosed every year. Alzheimers
World Class Extractions (PUMP.C), a newcomer in the extraction sector, signed an LOI to acquire Quadron Cannatech (QCC.C) today. This acquisition will put World Class
